KRAS and breast cancer: Due to the common dysregulation of the Ras/MAPK pathway in breast cancer, inhibition of NOX2-dependent mechanotransduction by oncogenic activation of KRas may play an important role in breast malignancies; however, the specific role for mechanically-activated NOX2 in breast and other epithelial cancers has yet to be defined.